Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
11 studies found for:    solanezumab
Show Display Options
RSS Create an RSS feed from your search for:
solanezumab
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Continued Safety Monitoring of Solanezumab in Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
2 Recruiting A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Solanezumab;   Drug: Placebo
3 Active, not recruiting Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Condition: Alzheimer's Disease
Interventions: Drug: Solanezumab;   Drug: Placebo
4 Completed A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
Condition: Alzheimer's Disease
Intervention: Drug: solanezumab
5 Recruiting Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Condition: Cognition Disorders
Interventions: Drug: Solanezumab;   Drug: Placebo
6 Completed Effect of LY2062430 on the Progression of Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430;   Drug: Placebo
7 Completed Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
8 Completed Effect of LY2062430 on the Progression of Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430;   Drug: Placebo
9 Completed Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430;   Drug: Placebo
10 Active, not recruiting Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Conditions: Alzheimers Disease;   Dementia;   Alzheimers Disease, Familial
Interventions: Drug: Gantenerumab;   Drug: Solanezumab;   Drug: Matching Placebo (Gantenerumab);   Drug: Matching Placebo (Solanezumab)
11 Recruiting A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
Conditions: Healthy;   Alzheimer's Disease;   Mild Cognitive Impairment
Interventions: Drug: LY2599666;   Drug: Solanezumab;   Drug: Placebo SC;   Drug: Placebo IV

Study has passed its completion date and status has not been verified in more than two years.